Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2010
07/28/2010CN101057861B Polycarbophil enteric coated medicinal composition
07/28/2010CN101016283B Preparation of yanhuning
07/28/2010CN101012201B Ligustrazine derivative, preparation method and medical use thereof
07/27/2010US7763752 such as 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentane-1-ol, used for treating autoimmune diseases, rheumatoid arthritis, psoriasis, dermatitis, asthma, hay fever or rejection of organ or bone morrow transplantation; side effect reduction
07/27/2010US7763751 such as N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine, useful for the prevention, treatment and diagnosis of nervous system disorders related to protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion protein and huntingtin gene
07/27/2010US7763748 Purification; therapy for skin disorders, acne ; demetallization; removal of impurities
07/27/2010US7763747 Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis
07/27/2010US7763738 ceramide-like inhibitors; novel intermediates formed during the synthesis; Glycosphingolipids
07/27/2010US7763733 such as (2S,3S,5S)-2,5-bis-[N [N [[N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino]-1,6-diphenyl-3-hydroxyhexane, used for the treatment of human immunodeficiency virus infection
07/27/2010US7763729 Bicyclic heteroaromatic derivatives
07/27/2010US7763723 Polysaccharide and composition from Antrodia camphorata and use thereof
07/27/2010US7763705 Viral peptides for use in activating immune response to treat and prevent viral infection
07/27/2010US7763662 reducing weight in mammals; Substituted with a thio, sulfoxy or sulfonyl group eg 5-Chloro-2-methylsulfonylindan-1-ol, 5-Chloro-2-(propane-2-sulfonyl)indan-1-ol, 5-Chloro-2-ethanesulfonylindan-1-ol
07/27/2010US7763661 such as 3-Bromo-4-(2,6-dibromo-3-nitro-4-pentafluorosulfanylphenoxy)-5-methanesulfonyl-2- methylnitrobenzene, used as chemical intermediates for drugs, diagnostic aids, liquid crystals, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and polymers
07/27/2010US7763660 administering 1-(5-methyl-2-propan-2-ylcyclohexyl)oxy-3-piperidin-1-ylpropan-2-ol, for the treatment fungal infection in humans and mammals; inhibitors of the budded-to-hyphal transition of yeasts
07/27/2010US7763659 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
07/27/2010US7763658 administering bis[thio-hydrazide amide] Compounds for treating multi-drug resistant cancer
07/27/2010US7763657 such as N-{-4-[3-(4-t-butylbenzyl)ureidomethyl]-2-vinylphenyl}methanesulfonamide, used as analgesics, and for treating psoriasis, pruritus, asthma, chronic obstructive pulmonary disease, urinary incontinence, inflammatory bowel disease, tinnitus and ischemia
07/27/2010US7763656 Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease
07/27/2010US7763655 Cosmetic compositions having carnitine creatinate and methods for using
07/27/2010US7763654 wherein the diffraction pattern by powder X-ray diffractometry has characteristic peaks at diffraction angles (2 theta ) of 9.0, 13.6, 18.7, 20.6 and 24.8; has a beta 3-adrenaline receptor stimulating effect and is useful as an agent for treating pollakiuria or urinary incontinence
07/27/2010US7763653 comprising the free bases of the local anesthetics prilocaine, lidocaine and bupivacaine in a weight ratio of 40-60%/25-45%/10-25%, respectively, the resulting mixture being a homogenous liquid having a melting point below 20 degrees C.
07/27/2010US7763652 such as 9-Deoxy-9 beta -chloro-16,17,18,19,20-pentanor-15-cyclohexyl-2,2,3,3,13,14-hexadehydro-6-thia-prostaglandin F1, useful as drugs for sleep induction
07/27/2010US7763651 Treating pain using selective antagonists of persistent sodium current
07/27/2010US7763650 Pharmaceutical compound and method
07/27/2010US7763649 Treating cardiac arrhythmia and/or cancerous and pre-cancerous cells by administering specific synthetic carotenoid analogs or derivatives either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation
07/27/2010US7763648 Oxa-steroids derivatives as selective progesterone receptor modulators
07/27/2010US7763647 Topical solution containing a chromane or chromene derivative
07/27/2010US7763646 beta-secretase inhibitors such as N-(3,5-difluorobenzyl)-N-{(2R)-2-hydroxy-3-[(3-iodobenzyl)amino]propyl}-5-methyl-N',N'-dipropylisophthalamide, used for reducing amyloid beta peptide formation
07/27/2010US7763645 Carvedilol dihydrogen phosphate monohydrate
07/27/2010US7763644 Such as 1-(1H-imidazol-1-ylmethyl)pyrrolidin-2-one; levetiracetam (SV2 protein family) binding site ligands; anticonvulsant activity
07/27/2010US7763643 Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
07/27/2010US7763642 Phenyl-sulfamates as aromatase inhibitors
07/27/2010US7763641 such as [(1S,2R)-2-hydroxy-3-[N-[4-(2-methylaminothiazol-4-yl)phenylsulfonyl]-N-(2-methylpropyl)amino]-1-(phenylmethyl)propyl]carbamic acid, [(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]ester, used for treating human immunodeficiency virus infections
07/27/2010US7763640 such as N-methoxy-N'-(2-chloropyrid-5-ylmethyl)nitroguanidine, formed by reacting N-nitro-N'-(2-chloropyrid-5-ylmethyl)-S-methylisothiourea and O-methylhydroxylamine; pesticides; insecticides
07/27/2010US7763639 1-ethyl-4-[2-fluoro-3-(methylsulfonyl)phenyl]piperidine, havinf therapeutic effects against disorders in the central nervous system, such as dyskinesia
07/27/2010US7763638 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
07/27/2010US7763637 Gastrointestinal disorders; selectivity, potency, pharmacokinetics, duration of action; minimal side effects
07/27/2010US7763636 N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
07/27/2010US7763635 Uniform concentration in blood; oral administration for bladder dysfunction disorders
07/27/2010US7763634 Inhibitors of janus kinases
07/27/2010US7763633 such as 6-[2-(4-Hydroxyphenyl)ethylamino]-11H-indolo[3,2-c]quinoline, used to inhibit both growth of cancer cells and activity of telomerase
07/27/2010US7763632 administering drugs succh as N-[2-diethylamino-5-{N-ethyl-N-(trifluoroacetyl)amino}pyrimidin-4-yl]-L-4'-{(pyrrolidin-1-yl) carbonyloxy}phenylalanine, for the treament asthma, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft versus host disease and arthritis
07/27/2010US7763631 substituted amino pyrimidine derivatives useful in the treatment or prevention of viral infections, in particular against human immunodeficiency virus (HIV), which is the aetiological agent of acquired immune deficiency syndrome (AIDS) in humans
07/27/2010US7763630 pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS)
07/27/2010US7763629 4-((R)-5-cyclopentyl-4-ethyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-ylamino)-3-methoxy-N-methylbenzamide, useful for treating or preventing autoimmune, inflammatory, proliferative, or hyperproliferative disease, a neurodegenerative disease, or an immunologically-mediated disease
07/27/2010US7763628 Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate
07/27/2010US7763627 2-pyridin-4-ylquinazolin-4- amine's such as N-cyclohexyl-2-pyridin-4-ylquinazolin-4- amine, used as tyrosine kinase inhibitors, for modulating cellular activities such as proliferation, differentiation, apoptosis, migration and chemoinvasion; antiproliferative agents and angiogenesis inhibitors
07/27/2010US7763626 composition for inhibition of opioid tolerance and opioid withdrawal-induced hyperalgesia comprising propentofylline, an opioid drug, and a pharmaceutically acceptable carrier, wherein said composition is administered intrathecally at a dose of propentofylline of 10 micrograms
07/27/2010US7763625 administering adenosine A2 receptor antagonists comprising xanthine derivatives such as 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione, for the treatment of headaches
07/27/2010US7763624 protein tyrosine kinase inhibitorssuch as 1-(but-3-enyl)-N3-(2,6-dimethylphenyl)-N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine, used for the treatment of autoimmune diseases and as antiproliferative or anticarcinogenic agents
07/27/2010US7763623 Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
07/27/2010US7763622 such as 5-methyl-6-(2-chloro-4-fluorophenyl)-7-(4-methylpiperidin-1-yl)-[1,2,4]-triazolo[1,5-a]pyrimidine, used for controlling phytopathogenic fungi; improved fungicidal activity
07/27/2010US7763621 3-[[6-[4-(1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl)-1-piperidinyl]-2,5-dimethyl-4-pyrimidinyl]amino]-N-[(phenylmethoxy)carbonyl]alanine, used for the treatment of osteoporosis, restenosis, arteriosclerosis, nephropathy or retinopathy
07/27/2010US7763620 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
07/27/2010US7763619 treating disorders of the outer retina with compounds with 5-HT1A agonist activity; age-related macular degeneration
07/27/2010US7763618 Pyridyl derivatives and their use as therapeutic agents
07/27/2010US7763617 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
07/27/2010US7763616 Chemokine receptor antagonists, used for the treatment of inflammatory diseases, autoimmune diseases, transplant rejection, infectious diseases, hypersensitivity responses, ophthalmic inflammation, diabetes, viral meningitis and tumors
07/27/2010US7763615 derivatives of ecteinascidins, particularly ecteinascidin 736, used for the treatment of lung, colon, kidney, prostate, cervical, ovarian, breast or pancreatic cancer, leukaemia or melanoma in mammals; reduced systemic toxicity and improved pharmacokinetics
07/27/2010US7763614 Isoquinoline potassium channel inhibitors
07/27/2010US7763613 Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
07/27/2010US7763612 such as 2S,3S,5R)-4-[5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoyloxymethoxycarbonyl]-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol, used as anticonvulsants and for the treatment of psychological, nervous system and/or metabolic disorders
07/27/2010US7763611 Aroylsemicarbazide derivatives against thromboembolic diseases
07/27/2010US7763610 cysteinyl leukotriene antagonists such as 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid, used for treating asthma, chronic obstructive pulmonary disease, pneumonia, rhinitis and as expectorants or antitussives
07/27/2010US7763609 Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example
07/27/2010US7763608 Factor Xa inhibitors
07/27/2010US7763607 Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
07/27/2010US7763606 2,4-benzodiazepine derivatives, used for treating cardiovascular diseases, cognitive and neurodegenerative diseases
07/27/2010US7763605 [1,4]benzodiazepines as vasopressin V2 receptor antagonists
07/27/2010US7763604 10-farnesyl-4,6,8-trihydroxy-dibenzodiazepin-11-one; ECO-4601; anticarcinogenic, antitumor agent; early stage of cancer; reducing side-effects on normal cells
07/27/2010US7763603 Manipulation of brain CDP-diacylglycerol and uses thereof
07/27/2010US7763602 Drug resistant Mycobacterium tuberculosis
07/27/2010US7763601 Using O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15); weight loss
07/27/2010US7763600 Nitric ester derivatives of hormones such as progesterone, used for preventing premature labor, increasing cervical dilatation, in hormone replacement therapy, as hypeortensive agents and for treating dysmenorrhea
07/27/2010US7763599 Retinoic esters with cholesterol; antiproliferative agents; disorders caused by abnormal cellular differentiation; psoriasis, cancers of skin, colon, lungs, breasts, prostate, or ovaries, leukemia, neuroblastomas, eczema, acne; improved wrinkle resistance, skin hydration, sebum secretions
07/27/2010US7763598 1 alpha -hydroxy-2-[3'-hydroxypropylidene]-20-methyl-19, 24, 25, 26, 27-pentanorvitamin D3, used as an anticarcinogenic agent, for the treatment of skin disorders, autoimmune diseases, inflammatory diseases, renal osteodystrophy, and/or prevention of obesity
07/27/2010US7763597 Salts
07/27/2010US7763596 Antiinflamamtory agents; immunosuppressants; antiproliferative agents; treating haematology; reduced harmful side-effects
07/27/2010US7763595 Method of treatment of skin with external preparation composition
07/27/2010US7763594 comprising synergistic hyaluronic acid and dermatan sulphate; improved joint mobility
07/27/2010US7763591 Hepatocyte growth factor gene as an active therapeutic agent; biodrugs; Parkinson's disease, Alzheimer's disease, spinal cord injury, diabetic peripheral neuritis, and ischemic cerebrovascular disorders (cerebral infarction, cerebral haemorrhage)
07/27/2010US7763589 Administering a vector construct that expresses an immunogenic portion of an antigen derived from a pathogen, and administering an immunogenic protein of said antigen, to generate an immune response
07/27/2010US7763588 Administering flavonoids and oxidation resistance compound; Alzheimer's disease; Parkinson's disease; Huntington's disease
07/27/2010US7763583 Endoparasiticidal compositions for topical application
07/27/2010US7763580 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring
07/27/2010US7763285 Polyacetylenic compounds
07/27/2010US7763284 Method for treating or preventing symptoms associated with menopause
07/27/2010US7763282 Quaternary compounds comprising propolis as the active substance
07/27/2010US7763280 Tiotropium containing powder formulation for inhalation
07/27/2010US7763278 As cholesterol lowering agents and for treatment of cardiovascular disorders
07/27/2010US7763277 drug delivering phosphorous or a platinum anti-cancer substance through an implant comprising a resorbable mesoporous silicon carrier material; biodegradable; administering micronutrient, or trace elements or minerals
07/27/2010US7763273 Method for reducing methane production emanating from the digestive activities of an animal
07/27/2010US7763263 Bis(polyoxyalkylene) fumarate for enhancing epidermal permeability barrier function; inhibiting amphiregulin expression, epidermal hyperproli- feration; heparin-binding epidermal growth factor expression-inducing agent to accelerate epidermal turnover, ameliorating agent for aged skin
07/27/2010US7763255 Therapeutic uses of Dunaliella powder
07/27/2010US7763249 Brain protein specific immunoglobulin for use in diagnosis, prevention and treatment of alzheimer's disease
07/27/2010US7763236 administering a formulation in the form of a toothpaste, mouthwash, mouth spray or chewing gum, comprising osteopontin effective to inhibit plaque bacterial growth on teeth enamel
07/27/2010CA2631535C Spirocyclic quinazoline derivatives as pde7 inhibitors
07/27/2010CA2629339C Pyrazolo[4,3-d]pyrimidin-5-yl) derivative used as pde5 inhibitors
07/27/2010CA2610166C Benzoquinolinesulfonamide derivatives useful as rho-kinase inhibitors